Content MFN Drug Pricing: Industry Pushes Back as Biotech R&D Funding Hangs in the Balance 24 March 2026
Podcast CDMO Consolidation “Inevitable” Without Business Model Shift, Warns Cell Therapy CEO 16 March 2026
Expert Insight Why FDA’s CRL wave isn’t a CMC crisis — and what biotechs should do instead 3 March 2026
Expert Insight China’s Biotech Ascent Reshapes Global Pharma Strategy, Dominates JPM26 Discussions 19 January 2026
Podcast Building Investor-Ready CMC Programs: Marta Kijanka’s Strategic Framework for Early-Stage Biotechs 20 October 2025